Evidence map›Paper›PMID 41987550›Full record

ArticleMolecular oncology2026

Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer.

Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuho EbataDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-5636-3236
Koji AndoDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-0149-1505
Hirofumi HasudaDepartment of Gastroenterological Surgery and Clinical Research Institute, Kyushu Medical Center, Fukuoka, Japan.
Koshi MimoriDepartment of Surgery, Kyushu University Beppu Hospital, Oita, Japan.
Elizabeth C UnanDepartment of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
Siddhartha PulukuriDepartment of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
Aahana TikuDepartment of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
Allison BergerTakeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Eiji OkiDepartment of Advanced Medicine and Innovative Technology, Kyushu University Hospital, Fukuoka, Japan.
Ajit BhartiDepartment of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
Tomoharu YoshizumiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge. We previously showed that camptothecin induces ubiquitin-proteasome pathway (UPP)-mediated topoI degradation. In this study, we investigated whether inhibition of UPP could prevent topoI degradation and restore camptothecin sensitivity. SN-38, an active metabolite of irinotecan, induced topoI degradation in irinotecan-resistant colorectal cancer cell lines, which was suppressed by ixazomib. The combination significantly enhanced cytotoxicity, colony inhibition, and reduced IC

Indexed as

Boron CompoundsCamptothecinColorectal NeoplasmsDNA Topoisomerases, Type IDrug Resistance, NeoplasmGlycineProteasome InhibitorsProteolysisTopoisomerase I InhibitorsAnimalsCell Line, TumorHumansIrinotecanMiceMice, NudeProteasome Endopeptidase ComplexBoron CompoundsCamptothecinDNA Topoisomerases, Type IGlycineIrinotecanixazomibProteasome Endopeptidase ComplexProteasome InhibitorsTopoisomerase I Inhibitorscolorectal canceririnotecan resistanceixazomibproteasome inhibitorSN‐38topoisomerase I

Identifiers

PMID41987550
PMCPMC13398833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.